Xcout Intel
SENSORION competitors & alternatives
The 12 closest competitors and alternatives to SENSORION among biotech companies — ranked by similarity to what SENSORION actually does, not by market-cap band.
Subscribe to see SENSORION’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About SENSORION
Sensorion is a French biopharmaceutical company developing therapies for inner-ear disorders, including hearing loss and vestibular diseases. Its products are intended for patients with debilitating auditory and balance-related conditions, serving healthcare providers and the broader biopharmaceutical market.
SENSORION at a glance
SENSORION is a biotech company headquartered in France. Xcout tracks 17 named people at SENSORION, including Fred Chereau (Directeur Général).
SENSORION leadership
- Fred ChereauDirecteur Général
- Laurène DanonDirectrice Financière
- Bernd SchmidtDirecteur des Opérations Techniques
- Christine Le BecDirectrice CMC Thérapie Génique
- Laurent DésiréResponsable du Développement Préclinique
- Rachel CooperDirectrice de l'Audiologie
11 more named people on record for SENSORION, with roles, board committees and tenure — see the full roster →
Top 12 SENSORION competitors
Ranked by semantic similarity — how close each company is to SENSORION by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
Spiral Therapeutics Inc. is a clinical-stage pharmaceutical company based in South San Francisco, California, focused on delivering targeted therapies for inner ear conditions.
Similar biotech company
GenSight Biologics is a clinical-stage biopharmaceutical company that develops gene therapies to treat neurodegenerative retinal diseases and central nervous system disorders. The company focuses on addressing conditions such as Leber Hereditary Optic Neuropathy (LHON), Retinitis Pigmentosa, and Geographic Atrophy using technologies like gene therapy, mitochondrial targeting sequences, and optogenetics.
Life Science
Acousia Therapeutics GmbH is a privately held biotechnology company founded in 2012 to develop therapeutics fighting hearing loss. Supported by a strong investor consortium, the company is based in Tübingen, Germany.
Biotechnology
Oricula Therapeutics LLC is a biotechnology company developing medications designed to prevent drug-induced hearing loss. Its lead product candidate, an oral medication called ORC-13661, aims to protect inner ear hair cells from the damaging side effects of aminoglycoside antibiotics.
Biotechnology
Skylark Bio is a biotechnology company developing precision-targeted, locally delivered gene therapies to treat genetic hearing loss and other single-gene disorders. The company's platform aims to restore natural biological processes and hearing function, addressing conditions that affect children and individuals with genetic communication impairments.
Biotechnology
Corteria Pharmaceuticals is a privately held biopharmaceutical company based in Paris, France, focused on developing first-in-class drugs for indications with high unmet medical need, particularly heart failure.
Biotechnology
Exeliom Biosciences is a clinical-stage biopharmaceutical company headquartered in France that develops novel therapeutic approaches harnessing microbiome-host interactions.
Biotechnology
Nexion Therapeutics is a biotechnology company focused on researching and developing innovative therapies designed to improve patient outcomes and enhance quality of life. The company serves the healthcare sector by advancing cutting-edge biotechnological solutions.
Similar biotech company
Domain Therapeutics is a French biopharmaceutical company focused on discovering and developing drugs that target G-protein-coupled receptors (GPCRs), including applications in oncology and immuno-oncology. It serves pharmaceutical and biotechnology partners through proprietary drug-discovery programs, technology platforms, and licensing or collaboration agreements.
Biotechnology
Aurion Biotech Inc. develops regenerative cell therapies for ophthalmology, focusing on treatments for corneal endothelial disease and vision loss. Its lead product, AURN001, is a combination therapy utilizing human corneal endothelial cells designed to restore corneal clarity and provide a minimally invasive alternative to traditional donor tissue transplantation. The company serves patients suffering from blindness and provides advanced treatment options for ophthalmologists.
Similar biotech company
Quantum Genomics was a French biopharmaceutical company focused on developing treatments for cardiovascular diseases, particularly difficult-to-treat or resistant hypertension. Its lead candidate, firibastat, was designed as a brain aminopeptidase A inhibitor for patients whose hypertension is not adequately controlled by existing therapies.
Similar biotech company
Valbiotis develops and sells plant-based dietary supplements and health products designed for consumers seeking general wellness and cardiometabolic support. The company's scientifically tested formulations target areas such as cholesterol management, metabolic health, circulation, sleep, and daily vitality.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of SENSORION and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for SENSORIONand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →